A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation.

A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation.

HIV-infected individuals rely on antiretroviral therapy (ART) to control viral replication. Despite abundant demonstrable benefits, the multiple limitations of ART point to the potential advantages of therapeutic vaccination approaches that could provide sustained host control of viral replication a...

Full description

Bibliographic Details
Main Authors: Panagiotis Vagenas, Meropi Aravantinou, Vennansha G Williams, Edith Jasny, Michael Piatak, Jeffrey D Lifson, Andres M Salazar, James L Blanchard, Agegnehu Gettie, Melissa Robbiani
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-09-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2943484?pdf=render

Internet

http://europepmc.org/articles/PMC2943484?pdf=render

Similar Items